Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Edward Kim

Vascular & Interventional Radiology New York, NY Medical Doctor

NPI 1851565543 CMS profile 357299

1176 5Th Ave, New York, NY 10029

Open in the dashboard

General payments

$830,758

753 records reported · program years 2019–2025

Research payments

$2,903

Paid to them · 11 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$24,745 paid to institutions, not to them · program years 2019–2021

Through program year 2025, Edward Kim of New York, NY is reported in the CMS Open Payments database as having received $830,758 across 753 general payments and $2,903 in research payments paid to them. Separately, studies naming them as principal investigator received $24,745 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $222,093 134
2025 Research $193 2
2024 General $159,293 156
2024 Research $1,141 1
2023 General $127,928 134
2023 Research $581 5
2022 General $112,477 132
2022 Research $676 1
2021 General $75,887 84
2021 Research $312 2
2020 General $81,069 53
2019 General $52,013 60

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edward Kim
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Edward Kim were reported at $222,093. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Edward Kim Vascular & Interventional Radiology median Middle half National median
2019 $52,013 $422 $125–$1,555 $163
2020 $81,069 $200 $68–$652 $114
2021 $75,887 $280 $99–$866 $132
2022 $112,477 $433 $137–$1,497 $149
2023 $127,928 $506 $152–$2,019 $160
2024 $159,293 $556 $175–$1,930 $164
2025 $222,093 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $632,926 542 payments
  2. Siemens Medical Solutions USA, Inc. $41,351 28 payments
  3. Biocompatibles, Inc. $27,222 23 payments
  4. Medical Device Business Services, Inc. $17,651 11 payments
  5. AstraZeneca Pharmaceuticals LP $17,169 17 payments
  6. Philips Electronics North America Corporation $13,977 15 payments
  7. Eisai Inc. $13,150 7 payments
  8. Ethicon US, LLC $11,240 44 payments
  9. Sirtex Medical Inc $10,000 3 payments
  10. Genentech USA, Inc. $9,184 11 payments
  11. Other $36,888 52 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $400,587 117 payments
  2. Consulting Fee $318,459 147 payments
  3. Travel and Lodging $64,537 162 payments
  4. Food and Beverage $27,675 320 payments
  5. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $12,050 3 payments
  6. Honoraria $4,450 2 payments
  7. Grant $1,800 1 payment
  8. Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program $1,200 1 payment
Products named General payments · program years 2019–2025
  1. TheraSphere Y90 Glass Microspheres 7.0 GBq (US Commercial) $261,032 108 payments
  2. TheraSphere Y90 Glass Microspheres 10 GBq $201,630 185 payments
  3. General - Therapies $29,042 13 payments
  4. THERASPHERE - BIO $26,888 15 payments
  5. General Therapies $24,275 18 payments
  6. GENERAL PAIN MANAGEMENT $18,438 12 payments
  7. Certus 140 $15,398 9 payments
  8. GENERAL - VASCULAR INTERVENTION $14,735 12 payments
  9. Lenvima $12,383 5 payments
  10. Therasphere $11,877 6 payments
  11. Other $144,612 258 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $1,762 10 payments
  2. Novartis Pharmaceuticals Corporation $1,141 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

27

Median for Diagnostic Radiology: 24

Drug cost

$98

Median for Diagnostic Radiology: $190

Branded share of claims

100%

Median for Diagnostic Radiology: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 27 $98

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,198 Part D prescribers listed as Diagnostic Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$50,245

Medicare's payments for the services billed

Medicare patients

68

Average age 74

Services billed

400

23 women, 45 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Diabetes 47%
Ischemic heart disease 44%
Chronic kidney disease 34%
Cancer 28%
Heart failure 22%
COPD 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Lenvima
  • Eisai Inc. $10,400
$10,400 — —
TECENTRIQ
  • Genentech USA, Inc. $3,383
$3,383 — —
IMFINZI
  • AstraZeneca Pharmaceuticals LP $111
$111 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

764 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular & Interventional Radiology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record